DeepMed Research

BAYLOR COLLEGE OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1900-10-30

Employees: 10K

Market Cap: -

Website: http://www.bcm.edu

Clinical Trials

Cognitive Behavior Therapy for Treating Anxiety in People With Dementia

Phase 1

Completed

Conditions: Dementia
Anxiety Disorders

Interventions: Behavioral: Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
Behavioral: Enhanced Usual Care (EUC)

First Posted Date: 2008-01-16

Last Posted Date: 2015-08-13

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 34

Registration Number: NCT00596284

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States

Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia

Phase 1

Terminated

Conditions: Severe Aplastic Anemia
Fanconi Anemia

Interventions: Biological: CAMPATH-1H
Biological: Anti-CD45
Drug: Fludarabine
Procedure: Stem cell infusion

First Posted Date: 2008-01-10

Last Posted Date: 2018-05-24

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 5

Registration Number: NCT00590460

Locations: 🇺🇸
Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease

Phase 2

Completed

Conditions: Cardiac Output, Low

Interventions: Drug: Placebo
Drug: Hydrocortisone

First Posted Date: 2008-01-10

Last Posted Date: 2016-05-26

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 18

Registration Number: NCT00590018

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Administration of Virus-Specific Cytotoxic T-Lymphocytes

Phase 1

Completed

Conditions: Adenovirus Infection

Interventions: Biological: CTL administration

First Posted Date: 2008-01-10

Last Posted Date: 2014-02-19

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 14

Registration Number: NCT00590083

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
National Institute of Health (NIH), Washington, District of Columbia, United States

Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: carbidopa-levodopa (Sinemet)
Drug: Parcopa

First Posted Date: 2008-01-10

Last Posted Date: 2023-03-14

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 20

Registration Number: NCT00590122

Locations: 🇺🇸
PDCMDC 6550 Fannin, Suite 1801, Houston, Texas, United States

CD19 Chimeric Receptor Expressing T Lymphocytes in B-Cell Non Hodgkin's Lymphoma, ALL & CLL

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
B Cell Lymphoma
Acute Lymphocytic Leukemia

Interventions: Genetic: CD19CAR-28-zeta T cells
Drug: Ipilimumab

First Posted Date: 2008-01-04

Last Posted Date: 2025-01-23

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 14

Registration Number: NCT00586391

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Kareniticin and cyclophosphamide

First Posted Date: 2008-01-04

Last Posted Date: 2012-05-15

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 15

Registration Number: NCT00586560

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT

Phase 1

Terminated

Conditions: FANCONI ANEMIA

Interventions: Procedure: CD34 selected haploidentical PBSCT
Drug: Fludarabine
Biological: T cell infusion
Biological: Campath 1h
Biological: anti-CD45

First Posted Date: 2008-01-04

Last Posted Date: 2014-03-04

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 1

Registration Number: NCT00586274

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation

Phase 1

Completed

Conditions: Leukemia
Cancer

Interventions: Biological: T-Cell Infusion Dose Level -1
Biological: T-Cell Infusion Dose Level 1
Biological: T-Cell Infusion Dose Level 2
Biological: T-Cell Infusion Dose Level 3
Biological: T-Cell Infusion- Dose Level 4

First Posted Date: 2008-01-04

Last Posted Date: 2020-01-21

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 11

Registration Number: NCT00586547

Locations: 🇺🇸
Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Drug: Protracted Oral Etoposide
Drug: IV Bolus Etoposide
Drug: Doxorubicin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Mesna
Drug: Hematopoietic Factor
Procedure: Primary tumor resection

First Posted Date: 2007-12-21

Last Posted Date: 2020-03-27

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 13

Registration Number: NCT00578864

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy